Treatment of helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease

D. Y. Graham, K. S. Hepps, Francisco C Ramirez, G. M. Lew, Z. A. Saeed

Research output: Contribution to journalArticle

274 Citations (Scopus)

Abstract

Background: We evaluated whether therapy designed to eradicate Helicobacter pylori infection resulted in a reduction in rebleeding in patients with peptic ulcer disease. Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy. No maintenance anti-ulcer therapy was given after ulcer healing. Methods: Patients Received ranitidine, 30(1 mg, or ranitidine plus triple therapy. Triple therapy consisted of tetracycline, 2g; metronidazole, 750 mg; and bismuth subsalicylate, 5 or 8 tablets (151 mg bismuth per tablet), and was administered for the first 2 weeks of treatment; ranitidine therapy was continued until the ulcer had healed or 16 weeks had elapsed. After ulcer healing, no maintenance antiulcer therapy was given. Development of ulcer recurrence with or without recurrent upper gastrointestinal bleeding was evaluated. Results: Thirty-one patients with major upper gastrointestinal bleeding from peptic ulcer were studied; 17 Received triple therapy and 14 ranitidine alone. Major rebleeding occurred significantly (p = 0.031) more often in those in the ranitidine group (28.6% compared with none (0% in the triple therapy group. Conclusion: Eradication of H. pylori infection reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease.

Original languageEnglish (US)
Pages (from-to)939-942
Number of pages4
JournalScandinavian Journal of Gastroenterology
Volume28
Issue number11
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Peptic Ulcer
Helicobacter pylori
Ranitidine
Ulcer
Therapeutics
Helicobacter Infections
Tablets
Maintenance
Hemorrhage
Recurrence
Bismuth
Gastrointestinal Hemorrhage
Metronidazole
Group Psychotherapy
Tetracycline
Endoscopy

Keywords

  • Antimicrobial therapy
  • Bismuth subsalicylate
  • Clinical trial
  • Duodenal ulcer
  • Gastric ulcer
  • Helicobacter pylori
  • Maintenance
  • Ranitidine
  • Ulcer recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. / Graham, D. Y.; Hepps, K. S.; Ramirez, Francisco C; Lew, G. M.; Saeed, Z. A.

In: Scandinavian Journal of Gastroenterology, Vol. 28, No. 11, 1993, p. 939-942.

Research output: Contribution to journalArticle

Graham, D. Y. ; Hepps, K. S. ; Ramirez, Francisco C ; Lew, G. M. ; Saeed, Z. A. / Treatment of helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. In: Scandinavian Journal of Gastroenterology. 1993 ; Vol. 28, No. 11. pp. 939-942.
@article{d3d80523b11640548df7dcb0f4d69e37,
title = "Treatment of helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease",
abstract = "Background: We evaluated whether therapy designed to eradicate Helicobacter pylori infection resulted in a reduction in rebleeding in patients with peptic ulcer disease. Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy. No maintenance anti-ulcer therapy was given after ulcer healing. Methods: Patients Received ranitidine, 30(1 mg, or ranitidine plus triple therapy. Triple therapy consisted of tetracycline, 2g; metronidazole, 750 mg; and bismuth subsalicylate, 5 or 8 tablets (151 mg bismuth per tablet), and was administered for the first 2 weeks of treatment; ranitidine therapy was continued until the ulcer had healed or 16 weeks had elapsed. After ulcer healing, no maintenance antiulcer therapy was given. Development of ulcer recurrence with or without recurrent upper gastrointestinal bleeding was evaluated. Results: Thirty-one patients with major upper gastrointestinal bleeding from peptic ulcer were studied; 17 Received triple therapy and 14 ranitidine alone. Major rebleeding occurred significantly (p = 0.031) more often in those in the ranitidine group (28.6{\%} compared with none (0{\%} in the triple therapy group. Conclusion: Eradication of H. pylori infection reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease.",
keywords = "Antimicrobial therapy, Bismuth subsalicylate, Clinical trial, Duodenal ulcer, Gastric ulcer, Helicobacter pylori, Maintenance, Ranitidine, Ulcer recurrence",
author = "Graham, {D. Y.} and Hepps, {K. S.} and Ramirez, {Francisco C} and Lew, {G. M.} and Saeed, {Z. A.}",
year = "1993",
doi = "10.3109/00365529309098288",
language = "English (US)",
volume = "28",
pages = "939--942",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Treatment of helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease

AU - Graham, D. Y.

AU - Hepps, K. S.

AU - Ramirez, Francisco C

AU - Lew, G. M.

AU - Saeed, Z. A.

PY - 1993

Y1 - 1993

N2 - Background: We evaluated whether therapy designed to eradicate Helicobacter pylori infection resulted in a reduction in rebleeding in patients with peptic ulcer disease. Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy. No maintenance anti-ulcer therapy was given after ulcer healing. Methods: Patients Received ranitidine, 30(1 mg, or ranitidine plus triple therapy. Triple therapy consisted of tetracycline, 2g; metronidazole, 750 mg; and bismuth subsalicylate, 5 or 8 tablets (151 mg bismuth per tablet), and was administered for the first 2 weeks of treatment; ranitidine therapy was continued until the ulcer had healed or 16 weeks had elapsed. After ulcer healing, no maintenance antiulcer therapy was given. Development of ulcer recurrence with or without recurrent upper gastrointestinal bleeding was evaluated. Results: Thirty-one patients with major upper gastrointestinal bleeding from peptic ulcer were studied; 17 Received triple therapy and 14 ranitidine alone. Major rebleeding occurred significantly (p = 0.031) more often in those in the ranitidine group (28.6% compared with none (0% in the triple therapy group. Conclusion: Eradication of H. pylori infection reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease.

AB - Background: We evaluated whether therapy designed to eradicate Helicobacter pylori infection resulted in a reduction in rebleeding in patients with peptic ulcer disease. Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy. No maintenance anti-ulcer therapy was given after ulcer healing. Methods: Patients Received ranitidine, 30(1 mg, or ranitidine plus triple therapy. Triple therapy consisted of tetracycline, 2g; metronidazole, 750 mg; and bismuth subsalicylate, 5 or 8 tablets (151 mg bismuth per tablet), and was administered for the first 2 weeks of treatment; ranitidine therapy was continued until the ulcer had healed or 16 weeks had elapsed. After ulcer healing, no maintenance antiulcer therapy was given. Development of ulcer recurrence with or without recurrent upper gastrointestinal bleeding was evaluated. Results: Thirty-one patients with major upper gastrointestinal bleeding from peptic ulcer were studied; 17 Received triple therapy and 14 ranitidine alone. Major rebleeding occurred significantly (p = 0.031) more often in those in the ranitidine group (28.6% compared with none (0% in the triple therapy group. Conclusion: Eradication of H. pylori infection reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease.

KW - Antimicrobial therapy

KW - Bismuth subsalicylate

KW - Clinical trial

KW - Duodenal ulcer

KW - Gastric ulcer

KW - Helicobacter pylori

KW - Maintenance

KW - Ranitidine

KW - Ulcer recurrence

UR - http://www.scopus.com/inward/record.url?scp=0027495920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027495920&partnerID=8YFLogxK

U2 - 10.3109/00365529309098288

DO - 10.3109/00365529309098288

M3 - Article

VL - 28

SP - 939

EP - 942

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 11

ER -